In the BioHarmony Drug Report Database
Onasemnogene abeparvovec
Zolgensma (onasemnogene abeparvovec) is a gene pharmaceutical. Onasemnogene abeparvovec was first approved as Zolgensma on 2019-05-24. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy.
Trade Name
|
Zolgensma |
|---|---|
Common Name
|
onasemnogene abeparvovec |
ChEMBL ID
|
CHEMBL4297240 |
Indication
|
spinal muscular atrophy |
Drug Class
|
Image (chem structure or protein)
